Form 4: Vaxcyte CFO Andrew Guggenhime Executes Stock Option and Sells Shares

Andrew Guggenhime, President and CFO of Vaxcyte, Inc., exercised stock options and sold a portion of his holdings on March 18, 2024, under a pre-arranged trading plan.

Summary

• On March 18, 2024, Andrew Guggenhime, the President and CFO of Vaxcyte, Inc., executed a stock option to purchase 8,000 shares of common stock at a price of $5.35 per share.
• Simultaneously, Guggenhime sold 7,764 shares at a weighted average price of $68.999, with prices ranging from $68.58 to $69.495.
• He also sold 236 shares at a weighted average price of $69.642, with prices ranging from $69.625 to $69.66.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 30, 2023.
• Following these transactions, Guggenhime directly owns 95,679 shares of common stock and holds options for 368,827 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were pre-planned under a Rule 10b5-1 trading plan, indicating routine financial management rather than a reflection of the executive's view on the company's prospects.

Industry Context

Insider transactions are routinely monitored by investors to gauge management's perspective on the company's valuation and future prospects. A pre-planned sale under Rule 10b5-1 suggests a pre-determined strategy for asset diversification or liquidity, rather than a reaction to immediate company events.

Comparison to Industry Standards

• Comparing Vaxcyte's insider trading activity to similar biotech companies like Moderna (MRNA) or BioNTech (BNTX) shows that such transactions are common, especially among executives holding significant equity.
• The use of Rule 10b5-1 plans is a standard practice to avoid accusations of trading on non-public information, aligning with industry best practices for corporate governance.
• The size and frequency of these transactions are typical for executives managing their personal portfolios, and the impact on the stock price is usually minimal unless the transactions are unusually large or frequent.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares sold compared to the company's total outstanding shares.
• Employees are unlikely to be significantly affected as the transactions are part of a pre-arranged plan and do not reflect any change in the company's operations or outlook.

Key Dates